STAT9h
Pharmalittle: We’re reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
Novo's Ozempic faces scrutiny over potential link to rare eye disease
Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two ...
FiercePharma7h
Novo Holdings set to close $16.5B Catalent buy in 'coming days' after deal clears antitrust hurdles
After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to ...
BioPharma Dive5h
Novo builds up manufacturing; Pepgen Duchenne trial put on hold
Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine ...
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...
devdiscourse10h
Healthcare Innovations: Novo Nordisk's Strategic Moves and Emerging Drug Trends
Novo Nordisk is investing $1.2 billion in a rare disease drugs facility in Denmark, weight-loss drugs surge American ...
Novo Nordisk Continues Robust Share Repurchase Program
Novo Nordisk ( (NVO) ) has shared an announcement.
Novo Nordisk says Catalent buyout to close soon as regulatory conditions met
Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected ...